Use of quinolones in the treatment of gastrointestinal infections
- 42 Downloads
Bacterial enteropathogens are responsible for between 40 % and 80 % of diarrheal illness depending upon the age of the persons affected and geographic area where illness occurs. Antibacterial agents will shorten the illness associated with enteric infection caused by enterotoxigenicEscherichia coli, Shigella spp. andCampylobacter jejuni. These drugs also are effective in the therapy of certain clinical conditions (presumably because they are due to the same agents) which are characterized by moderate to severe diarrhea with one or more of the following: high fever, dysentery (passage of bloody mucoid stools), or high leukocyte counts in stools. Antimicrobial agents are also effective in the therapy of travelers' diarrhea. The quinolone drugs have several advantages in the management of bacterial diarrhea where strains causing illness from nearly all regions of the world will show general susceptibility: high concentrations are achieved in the intestinal lumen following oral administration and resistance development is unusual. A quinolone probably represents the optimal agent for therapy of bacterial diarrhea in adults in areas where trimethoprim-resistant enteric pathogens are common.
KeywordsDiarrhea Quinolone Leukocyte Count Antibacterial Agent High Fever
Unable to display preview. Download preview PDF.
- 1.DuPont HL, Pickering LK Infections of the gastro-intestinal tract: microbiology, pathophysiology, and clinical features. Plenum, New York, 1980.Google Scholar
- 4.Murray BE Resistance ofShigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Reviews of Infectious Diseases 1986, 8, Supplement 2: 172–181.Google Scholar
- 7.Goosens H, De Mol P, Coignau H, Levy J, Grados O, Ghysels G, Habyaremye I, Butzler J Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR810 (a new cephalosporin), RU 28965 (a new macrolide), and other agents against enteropathogens. Antimicrobial Agents and Chemotherapy 1985, 27: 388–392.PubMedGoogle Scholar
- 9.O'Hare MD, Flemingham D, Ridgway GL, Grüneberg RN The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens. Drugs in Experimental and Clinical Research 1985, 11: 253–257.Google Scholar
- 12.Ling J, Kam KM, Lam AW, French GL Susceptibilities of Hong Kong isolates of multiply resistantShigella spp. to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones. Antimicrobial Agents and Chemotherapy 1988, 30: 20–23.Google Scholar
- 15.Areieri G, Griffith E, Gruenwaldt G, Heyd A, O'Brien B, Beeker N, August R Ciprofloxacin: an update on clinical experience. American Journal of Medicine 1987, 82, Supplement 4A: 381–386.Google Scholar
- 24.DuPont HL, Ericsson CD, Mathewson JJ, Johnson PC, DuPont MW Prevention and treatment of travelers' diarrhea. International Congress for Infectious Diseases, Montreal, 1990, Abstract.Google Scholar
- 30.McCormack JG Nalidixic acid for shigellosis. Lancet 1983, ii: 1091.Google Scholar
- 32.Haltalin KC, Nelson JD, Kusmiesz HT Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Archives of Diseases of Children 1973, 48: 305–312.Google Scholar
- 33.Gotuzzo E, Oberhelman RA, Maguina C, Berry SJ, Yi A, Guzman M, Ruiz R, Leon-Barua R, Sack RB Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. Antimicrobial Agents and Chemotherapy 1989, 33: 1101–1104.PubMedGoogle Scholar
- 41.Schlüter G: Toxicology of ciprofloxacin. In: Neu HC, Weuta H (ed): International Ciprofloxacin Workshop. Proceedings of the First Excerpta Medica, Amsterdam, 1986, p. 61–70.Google Scholar